[go: up one dir, main page]

PE43298A1 - Genes sinteticos de vih - Google Patents

Genes sinteticos de vih

Info

Publication number
PE43298A1
PE43298A1 PE1997000126A PE00012697A PE43298A1 PE 43298 A1 PE43298 A1 PE 43298A1 PE 1997000126 A PE1997000126 A PE 1997000126A PE 00012697 A PE00012697 A PE 00012697A PE 43298 A1 PE43298 A1 PE 43298A1
Authority
PE
Peru
Prior art keywords
hiv
expression
codes
codons
polynucleotide
Prior art date
Application number
PE1997000126A
Other languages
English (en)
Inventor
John W Shiver
Mary-Ellen Davies
Margaret A Liu
Helen C Perry
Daniel C Freed
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9607293.9A external-priority patent/GB9607293D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PE43298A1 publication Critical patent/PE43298A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE REFIERE A UN POLINUCLEOTIDO SINTETICO QUE COMPRENDE CODONES PERFECCIONADOS PARA LA EXPRESION EN EL HUESPED MAMIFERO DE LA PROTEINA env DEL HIV, EN DONDE DICHO POLINUCLEOTIDO SE SELECCIONA DE: V1Jns-tPA-HIV IIIB gp120 o V1Jns-tPA-gp143/SRV-1 3`-UTR, ENTRE OTROS. TAMBIEN SE REFIERE AL PROCEDIMIENTO DE INCREMENTAR LA EXPRESION DEL ADN QUE CODIFICA UNA PROTEINA DEL HIV, QUE COMPRENDE: (a) IDENTIFICAR LA UBICACION DE LOS CODONES PARA UN CORRECTO FRAGMENTO DE LA LECTURA ABIERTA; (b) COMPARAR LOS TIPOS DE CODONES DESORDENADOS PARA OBSERVAR LA FRECUENCIA DE USO POR LOS GENES HUMANOS; (c) REEMPLAZAR LOS CODONES DE TIPO DESORDENADO CON CODONES PERFECCIONADOS PARA UNA ALTA EXPRESION DE GENES HUMANOS; (d) PROBAR LA EXPRESION MEJORADA. EL POLINUCLEOTIDO ADMINISTRADO ADEMAS CON HIV ATENUADO, HIV MUERTO, PROTEINAS env, gag y pol DEL HIV Y COMBINACIONES DE LOS MISMOS, PROPORCIONAN UNA INMUNOPROFILAXIS EFECTIVA CONTRA LA INFECCION POR HIV ATRAVES DE LA INMUNIDAD POR ANTICUERPOS NEUTRALIZANTES Y MEDIANTE LA ESTIMULACION DE LA PROLIFERACION DE LAS CELULAS T CITOTOXICAS COOPERADORAS Y FUNCIONES EFECTORAS
PE1997000126A 1996-02-22 1997-02-21 Genes sinteticos de vih PE43298A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1208296P 1996-02-22 1996-02-22
GBGB9607293.9A GB9607293D0 (en) 1996-04-09 1996-04-09 Synthetic hiv env genes

Publications (1)

Publication Number Publication Date
PE43298A1 true PE43298A1 (es) 1998-08-29

Family

ID=26309076

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000126A PE43298A1 (es) 1996-02-22 1997-02-21 Genes sinteticos de vih

Country Status (27)

Country Link
EP (1) EP0904380B1 (es)
JP (1) JP2000505299A (es)
KR (1) KR19990087126A (es)
CN (1) CN1216064A (es)
AR (1) AR005930A1 (es)
AT (1) ATE309366T1 (es)
AU (1) AU729231B2 (es)
BG (1) BG102784A (es)
BR (1) BR9707672A (es)
CO (1) CO4600706A1 (es)
CZ (1) CZ266798A3 (es)
DE (1) DE69734585T2 (es)
EE (1) EE9800257A (es)
ES (1) ES2251734T3 (es)
HR (1) HRP970092A2 (es)
HU (1) HUP9901112A3 (es)
ID (1) ID16021A (es)
IL (1) IL125547A0 (es)
IS (1) IS4814A (es)
NO (1) NO983876L (es)
NZ (1) NZ331161A (es)
PE (1) PE43298A1 (es)
PL (1) PL328730A1 (es)
SK (1) SK112998A3 (es)
TR (1) TR199801615T2 (es)
WO (1) WO1997031115A2 (es)
YU (1) YU35498A (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
JP2000516445A (ja) * 1996-06-21 2000-12-12 メルク エンド カンパニー インコーポレーテッド 合成遺伝子を含むワクチン
US6696291B2 (en) 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
DE69836206T2 (de) * 1997-02-07 2007-08-23 Merck & Co., Inc. Synthetische hiv gag gene
US7105724B2 (en) 1997-04-04 2006-09-12 Board Of Regents Of University Of Nebraska Methods and materials for making and using transgenic dicamba-degrading organisms
EP1012257A4 (en) 1997-04-04 2004-08-18 Donald P Weeks ETHODES AND MATERIALS FOR THE PRODUCTION AND USE OF TRANSGENIC DICAMBA-DEGRADING ORGANISMS
AU2003200914B2 (en) * 1997-10-20 2007-02-01 Gtc Biotherapeutics, Inc. Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems
AP1219A (en) * 1997-10-20 2003-10-22 Gtc Biotherapeutics Inc Novel modified MSP-1 nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
WO2000039304A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1535995A1 (en) * 1998-12-31 2005-06-01 Chiron Corporation Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof
EP1433851A3 (en) * 1998-12-31 2004-10-13 Chiron Corporation Improved expression of HIV polypeptides and production of virus-like particles
EP1141313A2 (en) * 1998-12-31 2001-10-10 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US6395714B1 (en) * 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
EP1165798A2 (en) 1999-03-29 2002-01-02 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
CA2378539A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
WO2001032901A1 (en) 1999-11-01 2001-05-10 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
WO2001045748A1 (en) * 1999-12-22 2001-06-28 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol
GB0014288D0 (en) 2000-06-10 2000-08-02 Smithkline Beecham Biolog Vaccine
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
CN1549730A (zh) * 2000-10-04 2004-11-24 ���������Ǵ�ѧ�й��� 黄病毒和瘟病毒衣壳蛋白的组成和使用方法
KR20020059856A (ko) * 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
MXPA04002631A (es) * 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
US7399467B2 (en) 2003-12-23 2008-07-15 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
US7855326B2 (en) 2006-06-06 2010-12-21 Monsanto Technology Llc Methods for weed control using plants having dicamba-degrading enzymatic activity
BRPI0717640A2 (pt) 2006-10-16 2013-11-12 Monsato Technology Llc Processo e composições para aumentar a saúde de plantas
US7838729B2 (en) 2007-02-26 2010-11-23 Monsanto Technology Llc Chloroplast transit peptides for efficient targeting of DMO and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2153593C (en) * 1993-01-26 2010-04-13 David B. Weiner Compositions and methods for delivery of genetic material
EP0740704A1 (en) * 1994-01-27 1996-11-06 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
US6630455B1 (en) * 1995-01-13 2003-10-07 Vanderbilt University Methods for inducing mucosal immune responses
JPH08198774A (ja) * 1995-01-20 1996-08-06 Terumo Corp Ｄｎａワクチン

Also Published As

Publication number Publication date
AU729231B2 (en) 2001-01-25
YU35498A (sh) 1999-07-28
EE9800257A (et) 1999-02-15
HUP9901112A2 (hu) 1999-07-28
CZ266798A3 (cs) 1999-03-17
PL328730A1 (en) 1999-02-15
JP2000505299A (ja) 2000-05-09
CO4600706A1 (es) 1998-05-08
TR199801615T2 (xx) 1998-11-23
DE69734585D1 (de) 2005-12-15
KR19990087126A (ko) 1999-12-15
SK112998A3 (en) 2000-04-10
BG102784A (en) 1999-05-31
NO983876D0 (no) 1998-08-21
ES2251734T3 (es) 2006-05-01
AU2124697A (en) 1997-09-10
IS4814A (is) 1998-07-30
ID16021A (id) 1997-08-28
DE69734585T2 (de) 2006-08-10
WO1997031115A3 (en) 1997-10-09
BR9707672A (pt) 1999-04-13
IL125547A0 (en) 1999-03-12
HRP970092A2 (en) 1998-04-30
NO983876L (no) 1998-10-21
ATE309366T1 (de) 2005-11-15
CN1216064A (zh) 1999-05-05
NZ331161A (en) 2000-03-27
AR005930A1 (es) 1999-07-21
HUP9901112A3 (en) 2001-06-28
EP0904380B1 (en) 2005-11-09
EP0904380A2 (en) 1999-03-31
WO1997031115A2 (en) 1997-08-28

Similar Documents

Publication Publication Date Title
PE43298A1 (es) Genes sinteticos de vih
AR247590A1 (es) Una secuencia de adn que codifica derivados de factor viii humano recombinante y un procedimiento para su obtencion
MX9204685A (es) Secuencia de adn que codifica una proteina superficial externa (ospa) o derivado de la misma composicion de vacuna qe comprende tal proteina.
ES2126620T3 (es) Retrovirus del grupo de los vih y su utilizacion.
Chanh et al. Synthetic peptides homologous to HIV transmembrane glycoprotein suppress normal human lymphocyte blastogenic response
PE20060577A1 (es) Composiciones inmunogenicas y vacunas que comprenden fusiones de polipeptidos y polinucleotidos de vih
AR003425A1 (es) Poxvirus recombinante de mapache, vacuna para uso en gatos y uso de poxvirus para preparar una vacuna util para evitar o para disminuir la enfermedad causada por el virus de inmunodeficiencia felina (fiv)
ES2178153T3 (es) Una mezcla estsabilizada que comprende fibrinogeno.
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
ES2181717T3 (es) Implante biocompatible para la expresion y la secrecion in vivo de un compuesto terapeutico.
ES2124922T3 (es) Peptidos derivados de un retrovirus del grupo hiv y su uso.
ES2144399T3 (es) Clonado del adn de virus de anemia de los pollos.
ES2134197T3 (es) Vacunas contra el virus del herpes simplex vp16.
AR013528A1 (es) PROTEíNA-2 QUIMIOTÁCTICA MONOCíTICA (MCP-2) HUMANA AMINO TERMINALMENTE TRUNCADA, MOLÉCULA DE ADN QUE LA CODIFICA, VECTOR DE EXPRESIoN Y CÉLULA HUÉSPED CORRESPONDIENTES, PROCESO RECOMBINANTE PARA PREPARAR DICHAS PROTEíNAS, USO DE DICHAS PROTEíNAS PARA LA FABRICACIoN DE UN MEDICAMENTO uTIL PARA LA TER
ES2115622T3 (es) Clones moleculares de hiv-1 y usos de los mismos.
AR018489A1 (es) Uso de una celula realizada geneticamente que comprende dna que codifica una proteina de gen de activacion de linfocito 3 (lag-3) transmembrana y de dicha proteina para la fabricacion de un medicamento util para inducir la proteccion del rechazo de injerto y uso de moleculas antisentido de las misma
ES2066510T3 (es) Nuevos polipeptidos con afinidad para lipopolisacaridos y sus usos.
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
ES2069742T3 (es) Proteina de la capsida del calicivirus felino y secuencia nucleotida.
ES2054769T3 (es) Polipeptidos hiv-2 recombinantes.
ES2156902T3 (es) Peptidos que inducen la produccion de anticuerpos neutralizantes contra cepas de vih-1 geneticamente divergentes.
AR004567A1 (es) Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi.
BR9608626A (pt) Peptédeo preparação farmacéutica e uso de um peptídeo
ES2095899T3 (es) Peptidos de la proteina gag de vih, su preparacion y uso.
AR245958A1 (es) Procedimiento para la preparacion de polipeptidos de interleucina-1alfa

Legal Events

Date Code Title Description
FC Refusal